Sensex
82,069.47 profit arw 707.60 (0.87%)
Nifty
25,009.65 profit arw 216.40 (0.87%)
Nasdaq
18,355.20 profit arw -497.09 (-2.64%)
logo img

GET IN TOUCH

GET IN TOUCH

Refresh Captcha
Equity

As on : 18-Jun-2025
Hot Pursuit
18-Jun-2025     12:51

Alembic Pharma receives USFDA EIR for Karakhadi API facility

The inspection was conducted at the API-III facility from 17th March 2025 to 21st March 2025.

Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world. Its research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the USFDA.

The company's consolidated net profit declined 12% to Rs 156.89 crore despite a 16.7% jump in net sales to Rs 1,769.64 crore in Q4 FY25 over Q4 FY24.

Shares of Alembic Pharmaceuticals shed 0.78% to Rs 962.70 on the BSE.

Powered by Capital Market - Live News

INDIAN INDICES

Sensex

82,069.47 707.60 (0.87%)

Nifty

25,009.65 216.40 (0.87%)

GLOBAL INDICES

USD

85.75 0.06 (0.95%)

NASDAQ
HANG SENG

23,237.75 -472.95(-1.99%)